Company Overview - DexCom, Inc. (DXCM) is a medical device company with a market cap of $26.6 billion, specializing in continuous glucose monitoring (CGM) systems for diabetes and metabolic health management globally [1] Stock Performance - Over the past 52 weeks, DXCM shares have declined by 22.8%, underperforming the S&P 500 Index, which gained 14.4% during the same period [2] - Year-to-date, DXCM stock has risen by 2.7%, slightly outperforming the S&P 500's 1.4% gain [2] - The stock has also lagged behind the State Street Health Care Select Sector SPDR ETF (XLV), which rose by 6.2% over the past 52 weeks [3] Recent Financial Results - In Q3 2025, DexCom reported an adjusted EPS of $0.61 and revenue of $1.21 billion, both exceeding expectations [4] - Despite the strong financial results, shares fell by 14.6% the following day due to a cut in 2025 adjusted gross margin guidance from 62% to approximately 61% [4] - Management's decision not to provide 2026 guidance raised concerns about potential growth falling below market expectations and highlighted risks related to the D7 product execution [4] Analyst Expectations - For the fiscal year ending December 2025, analysts project a 26.2% year-over-year increase in adjusted EPS to $2.07 [5] - The company's earnings surprise history is mixed, with two beats and two misses in the last four quarters [5] - Among 28 analysts covering the stock, the consensus rating is a "Strong Buy," supported by 22 "Strong Buy" ratings, one "Moderate Buy," four "Holds," and one "Strong Sell" [5] Analyst Ratings - On January 20, TD Cowen analyst Josh Jennings reaffirmed a "Buy" rating on DexCom, maintaining a price target of $84 [6]